BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...

In a significant shift for the treatment landscape of essential thrombocythemia (ET), the US National Comprehensive Cancer Network (NCCN) has designated ropeginterferon alfa-2b-njft (Besremi) as a ...

The LARA trial (NCT04699071), a multi-center, single-arm, phase 2 study, found that combining pembrolizumab (Keytruda) with ...

Ancestry-specific biomarkers, such as POLB, could reshape diagnostic and prognostic approaches in head and neck cancer. New ...

Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...

A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...

HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

Dr. Shune continues the case discussion by describing disease progression following second-line therapy and outlining her approach to third-line treatment selection in cGVHD. After initiating systemic ...

A 52-year-old woman experiences chronic GvHD post-stem cell transplant, showcasing complex symptoms and treatment challenges. Discover her journey and management strategies. Dr. Shune discusses how ...

The FDA has granted fast track designation (FTD) to LBL-034, an investigational GPRC5D/CD3 bispecific T-cell engager (BiTE), for patients with relapsed/refractory multiple myeloma (R/R MM).

In an interview with Targeted Oncology, Filippo Pietrantonio, MD, discusses the safety and toxicity management of amivantamab ...